comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-11 16:24:18 - browse：5

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： The dental labor crisis is a moment of opportunity

hotspot

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

'Revelatory' study finds a smoking impact that remains after quitting

Some dementia cases could be undiagnosed liver disease

Private equity deals in Medicare Advantage declines

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Robert F. Kennedy is pitching centrism on health, even on abortion

Medicare proposal to cover medical devices draws a mixed reaction

Vertex non

Jerome Adams on the need for new antivirals for Covid

Vaccine advisory panel ACIP left half staffed by HHS

Trump demands the U.S. pay no more for drugs than other countries … again

How digital tools helped lower hypertension in marginalized patients

23andMe had bad news about my health. I wish a person had delivered it

Cybersecurity threat forces Lurie Children's to take systems offline

entertainment

Cognito secures funding to test medical device for Alzheimer's

Medicare Advantage proposed rates disappoint insurers

Cybersecurity threat forces Lurie Children's to take systems offline

Private equity deals in Medicare Advantage declines

Why did Pfizer dish out millions for a Super Bowl ad?

Novo Nordisk to expand supply of Wegovy for U.S. patients

hotspot

hotspot

focus

focus